SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
14.62 EUR
+0.26 (+1.81%)
1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. While 1SXP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- 1SXP had positive earnings in the past year.
- 1SXP had a positive operating cash flow in the past year.
- 1SXP had positive earnings in each of the past 5 years.
- In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 9.16%, 1SXP belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 16.42%, 1SXP belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
- 1SXP's Return On Invested Capital of 13.06% is amongst the best of the industry. 1SXP outperforms 90.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is significantly above the industry average of 9.00%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
- 1SXP has a Profit Margin of 14.85%. This is in the better half of the industry: 1SXP outperforms 75.00% of its industry peers.
- In the last couple of years the Profit Margin of 1SXP has grown nicely.
- The Operating Margin of 1SXP (18.95%) is better than 75.00% of its industry peers.
- In the last couple of years the Operating Margin of 1SXP has grown nicely.
- Looking at the Gross Margin, with a value of 33.71%, 1SXP is doing worse than 70.00% of the companies in the same industry.
- 1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1SXP is still creating some value.
- Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
- Compared to 5 years ago, 1SXP has about the same amount of shares outstanding.
- 1SXP has a better debt/assets ratio than last year.
2.2 Solvency
- The Debt to FCF ratio of 1SXP is 2.43, which is a good value as it means it would take 1SXP, 2.43 years of fcf income to pay off all of its debts.
- 1SXP's Debt to FCF ratio of 2.43 is amongst the best of the industry. 1SXP outperforms 90.00% of its industry peers.
- 1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- With an excellent Debt to Equity ratio value of 0.09, 1SXP belongs to the best of the industry, outperforming 95.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.44
WACC9.07%
2.3 Liquidity
- A Current Ratio of 1.50 indicates that 1SXP should not have too much problems paying its short term obligations.
- With a decent Current ratio value of 1.50, 1SXP is doing good in the industry, outperforming 70.00% of the companies in the same industry.
- A Quick Ratio of 1.12 indicates that 1SXP should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.12, 1SXP is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- The earnings per share for 1SXP have decreased by -2.02% in the last year.
- 1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.78% yearly.
- The Revenue has been growing slightly by 3.04% in the past year.
- Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 11.04% on average per year.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
- The Earnings Per Share is expected to grow by 12.98% on average over the next years. This is quite good.
- 1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.13% yearly.
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 15.07, 1SXP is valued correctly.
- Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 90.00% of the companies listed in the same industry.
- 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
- 1SXP is valuated correctly with a Price/Forward Earnings ratio of 14.25.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 90.00% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of 1SXP to the average of the S&P500 Index (24.30), we can say 1SXP is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.07 | ||
| Fwd PE | 14.25 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 1SXP is valued cheaper than 90.00% of the companies in the same industry.
- 75.00% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 62.62 | ||
| EV/EBITDA | 8.27 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- 1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.62
PEG (5Y)1.09
EPS Next 2Y11.1%
EPS Next 3Y11.63%
5. Dividend
5.1 Amount
- 1SXP has a Yearly Dividend Yield of 1.20%.
- The stock price of 1SXP dropped by -28.20% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
- 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.00% of the companies in the same industry.
- Compared to the average S&P500 Dividend Yield of 1.86, 1SXP is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.2% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
FRA:1SXP (1/22/2026, 2:36:39 PM)
14.62
+0.26 (+1.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-11 2025-12-11/amc
Earnings (Next)02-11 2026-02-11
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.20B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target21.23 (45.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.2% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.74%
PT rev (3m)-29.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)-10.89%
EPS NY rev (3m)-15.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.07 | ||
| Fwd PE | 14.25 | ||
| P/S | 2.23 | ||
| P/FCF | 62.62 | ||
| P/OCF | 12.24 | ||
| P/B | 2.47 | ||
| P/tB | 2.55 | ||
| EV/EBITDA | 8.27 |
EPS(TTM)0.97
EY6.63%
EPS(NY)1.03
Fwd EY7.02%
FCF(TTM)0.23
FCFY1.6%
OCF(TTM)1.19
OCFY8.17%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)2.62
PEG (5Y)1.09
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROCE | 16.33% | ||
| ROIC | 13.06% | ||
| ROICexc | 13.46% | ||
| ROICexgc | 13.83% | ||
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% | ||
| FCFM | 3.57% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 182.22% | ||
| Cap/Sales | 14.68% | ||
| Interest Coverage | 11.84 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 24.01% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | N/A |
F-Score6
WACC9.07%
ROIC/WACC1.44
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y16.53%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 5.75% in the next year.